{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T03:18:15Z","timestamp":1776223095439,"version":"3.50.1"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"S1","license":[{"start":{"date-parts":[[2023,1,24]],"date-time":"2023-01-24T00:00:00Z","timestamp":1674518400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,1,24]],"date-time":"2023-01-24T00:00:00Z","timestamp":1674518400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Reprod Health"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Availability of quality-assured medical abortion medicines plays a crucial role in providing comprehensive abortion care. However, access to these medicines is still restricted for many abortion seekers. Increasing availability of affordable, quality-assured mifepristone and misoprostol is important to improve access to safe medical abortion services. Driven by the outcomes of a global consultation hosted by the World Health Organization and the Swedish International Development Cooperation Agency in 2018, we decided to holistically examine access to medical abortion medicines from supply to demand. The overarching principle of the national landscape assessments was to generate evidence to support policy dialog and policymaking that is contextual to the needs of the country. This paper aims to describe the framework and methodological approach used in the World Health Organization landscape assessments of medical abortion medicines at country-level.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>A country assessment protocol was developed to guide the methodology of the World Health Organization landscape assessments. The assessment protocol included adaptation of an existing availability framework, an online desk review and literature review for existing data available for the country of interest, country-level key informant interviews, and analysis of the data to identify barriers and opportunities to improve medical abortion availability.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>The availability framework and methodology will allow the identification of key barriers that limit readiness of medical abortion medicines, and the development of opportunities to overcome those barriers. The national landscape assessments will provide directions for future investments and offer guidance for policy and programming on medical abortion care.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12978-022-01530-7","type":"journal-article","created":{"date-parts":[[2023,1,24]],"date-time":"2023-01-24T18:02:37Z","timestamp":1674583357000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["In-country availability of medical abortion medicines: a description of the framework and methodology of the WHO landscape assessments"],"prefix":"10.1186","volume":"20","author":[{"given":"Ulrika","family":"Rehnstr\u00f6m Loi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ndola","family":"Prata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amy","family":"Grossman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonella","family":"Lavelanet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natalie","family":"Williams","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bela","family":"Ganatra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,1,24]]},"reference":[{"key":"1530_CR1","unstructured":"World Health Organization. Prequalified active pharmaceutical ingredients (APIs). Geneva; 2002. https:\/\/extranet.who.int\/pqweb\/medicines\/active-pharmaceutical-ingredients. Accessed 10 May 2022."},{"issue":"1","key":"1530_CR2","first-page":"1982460","volume":"29","author":"J Durocher","year":"2021","unstructured":"Durocher J, Kilfedder C, Frye LJ, Winikoff B, Srinivasan K. A descriptive analysis of medical abortion commodity availability and pricing at retail outlets in 44 countries across four regions globally. Sex Reprod Health Matters. 2021;29(1):1982460.","journal-title":"Sex Reprod Health Matters"},{"key":"1530_CR3","unstructured":"Mann Global Health. Landscape assessment: leveraging the role of national distributors to increase access to MA combi-packs in Africa. 2019. https:\/\/www.rhsupplies.org\/uploads\/tx_rhscpublications\/Landscape_Assessment_Combi-Packs_RHSC_01.pdf. Accessed 1 Nov 2021."},{"key":"1530_CR4","unstructured":"Gynuity Health Projects. Map of mifepristone approvals. https:\/\/gynuity.org\/assets\/resources\/mapmife-en.pdf. Accessed 9 Mar 2021."},{"key":"1530_CR5","unstructured":"Bower J, Romero M, Chinery L. Market assessment for medical abortion in Argentina. 2001. https:\/\/www.rhsupplies.org\/uploads\/tx_rhscpublications\/Market_Assessment_for_Medical_Abortion_Drugs_in_Argentina.pdf. Accessed 1 Nov 2022."},{"issue":"2","key":"1530_CR6","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/j.ijgo.2008.12.016","volume":"105","author":"MM Fernandez","year":"2009","unstructured":"Fernandez MM, Coeytaux F, de Leon RG, Harrison DL. Assessing the global availability of misoprostol. Int J Gynaecol Obstet. 2009;105(2):180\u20136.","journal-title":"Int J Gynaecol Obstet"},{"issue":"3","key":"1530_CR7","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1363\/3816412","volume":"38","author":"B Winikoff","year":"2012","unstructured":"Winikoff B, Sheldon W. Use of medicines changing the face of abortion. Int Perspect Sex Reprod Health. 2012;38(3):164\u20136.","journal-title":"Int Perspect Sex Reprod Health"},{"issue":"3","key":"1530_CR8","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1136\/jfprhc-2014-100990","volume":"41","author":"P Harvey","year":"2015","unstructured":"Harvey P. Medical abortion: the hidden revolution. J Fam Plann Reprod Health Care. 2015;41(3):193\u20136.","journal-title":"J Fam Plann Reprod Health Care"},{"issue":"Suppl 1","key":"1530_CR9","doi-asserted-by":"publisher","first-page":"S16","DOI":"10.1016\/j.ijgo.2013.02.003","volume":"121","author":"KR Culwell","year":"2013","unstructured":"Culwell KR, Hurwitz M. Addressing barriers to safe abortion. Int J Gynaecol Obstet. 2013;121(Suppl 1):S16\u20139.","journal-title":"Int J Gynaecol Obstet"},{"issue":"6","key":"1530_CR10","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1093\/humupd\/dmaa026","volume":"26","author":"LE O'Shea","year":"2020","unstructured":"O\u2019Shea LE, Hawkins JE, Lord J, Schmidt-Hansen M, Hasler E, Cameron S, et al. Access to and sustainability of abortion services: a systematic review and meta-analysis for the National Institute of Health and Care Excellence-new clinical guidelines for England. Hum Reprod Update. 2020;26(6):886\u2013903.","journal-title":"Hum Reprod Update"},{"issue":"6","key":"1530_CR11","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1016\/j.rbmo.2021.02.014","volume":"42","author":"M Hennessy","year":"2021","unstructured":"Hennessy M, Dennehy R, Meaney S, Linehan L, Devane D, Rice R, et al. Clinical practice guidelines for recurrent miscarriage in high-income countries: a systematic review. Reprod Biomed Online. 2021;42(6):1146\u201371.","journal-title":"Reprod Biomed Online"},{"key":"1530_CR12","unstructured":"World Health Organization. Abortion care guideline. Geneva: World Health Organization; 2022. Licence: CC BY-NC-SA 3.0 IGO. https:\/\/apps.who.int\/iris\/handle\/10665\/349316. Accessed 5 May 2022."},{"issue":"8","key":"1530_CR13","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1080\/17441692.2011.594074","volume":"6","author":"D Lee","year":"2011","unstructured":"Lee D. Access: How do good health technologies get to poor people in poor countries? Glob Public Health. 2011;6(8):914\u20136.","journal-title":"Glob Public Health"},{"issue":"7","key":"1530_CR14","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1016\/S0277-9536(02)00491-4","volume":"57","author":"L Conteh","year":"2003","unstructured":"Conteh L, Hanson K. Methods for studying private sector supply of public health products in developing countries: a conceptual framework and review. Soc Sci Med. 2003;57(7):1147\u201361.","journal-title":"Soc Sci Med"},{"key":"1530_CR15","unstructured":"Schocken C, Tanuku D, Beecroft R, Chang C. Accelovate maternal health drug business assessments user guide. https:\/\/marketbookshelf.com\/wp-content\/uploads\/2017\/05\/Maternal-Health-Drug-Business-Assessment-User-Guide-revlogo.pdf. Accessed 10 Nov 2021."},{"key":"1530_CR16","unstructured":"Venture Strategies Innovations. Availability case study: misoprostol in Tanzania 2012. https:\/\/bixby.berkeley.edu\/publication\/availability-case-study\/. Accessed 10 Nov 2021."},{"key":"1530_CR17","unstructured":"Barnes J, Vail J, Crosby D. Total market initiatives for reproductive health. Bethesda, MD: Strengthening Health Outcomes through the Private Sector Project, Abt Associate; 2012. https:\/\/www.rhsupplies.org\/uploads\/tx_rhscpublications\/Total%20Market%20Initiatives%20for%20Reproductive%20Health.pdf. Accessed 10 Nov 2021."},{"key":"1530_CR18","unstructured":"DELIVER. Monitoring and evaluation indicators for assessing logistics systems performance. DELIVER, for the U.S. Agency for International Development. 2008. http:\/\/iaphl.org\/wp-content\/uploads\/2016\/05\/M_E_indicators_hdbk.pdf. Accessed 10 Oct 2021."},{"key":"1530_CR19","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.bpobgyn.2019.06.002","volume":"62","author":"AF Lavelanet","year":"2020","unstructured":"Lavelanet AF, Johnson BR Jr, Ganatra B. Global Abortion Policies Database: a descriptive analysis of the regulatory and policy environment related to abortion. Best Pract Res Clin Obstet Gynaecol. 2020;62:25\u201335.","journal-title":"Best Pract Res Clin Obstet Gynaecol"},{"issue":"10082","key":"1530_CR20","doi-asserted-by":"publisher","first-page":"1881","DOI":"10.1016\/S0140-6736(17)31209-6","volume":"389","author":"VJ Wirtz","year":"2017","unstructured":"Wirtz VJ, Hogerzeil HV, Gray AL, Lancet Commission on Essential Medicines P. Essential medicines for universal health coverage\u2014Authors\u2019 reply. Lancet. 2017;389(10082):1881\u20132.","journal-title":"Lancet"},{"key":"1530_CR21","unstructured":"Center for Reproductive Rights. World abortion laws. https:\/\/maps.reproductiverights.org\/worldabortionlaws. Accessed 20 May 2021."},{"key":"1530_CR22","unstructured":"World Health Organization. Global abortion policies database. http:\/\/srhr.org\/abortion-policies\/. Accessed 20 May 2021."},{"issue":"1","key":"1530_CR23","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1007\/s40199-019-00268-1","volume":"27","author":"M Afzali","year":"2019","unstructured":"Afzali M, Khorasani E, Alvandi M, Sabbagh-Bani-Azad M, Sharif Z, Saiyarsarai P, et al. Providing a framework for assessment of the access to medicine. Daru. 2019;27(1):243\u201354.","journal-title":"Daru"},{"key":"1530_CR24","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1186\/s12889-015-1502-2","volume":"15","author":"U Rehnstrom Loi","year":"2015","unstructured":"Rehnstrom Loi U, Gemzell-Danielsson K, Faxelid E, Klingberg-Allvin M. Health care providers\u2019 perceptions of and attitudes towards induced abortions in sub-Saharan Africa and Southeast Asia: a systematic literature review of qualitative and quantitative data. BMC Public Health. 2015;15:139.","journal-title":"BMC Public Health"},{"issue":"Suppl 1","key":"1530_CR25","doi-asserted-by":"publisher","first-page":"S40","DOI":"10.1016\/j.ijgo.2012.05.009","volume":"118","author":"R Acharya","year":"2012","unstructured":"Acharya R, Kalyanwala S. Knowledge, attitudes, and practices of certified providers of medical abortion: evidence from Bihar and Maharashtra, India. Int J Gynaecol Obstet. 2012;118(Suppl 1):S40\u20136.","journal-title":"Int J Gynaecol Obstet"},{"issue":"1","key":"1530_CR26","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1111\/j.1728-4465.2011.00263.x","volume":"42","author":"FE Okonofua","year":"2011","unstructured":"Okonofua FE, Hammed A, Abass T, Mairiga AG, Mohammed AB, Adewale A, et al. Private medical providers\u2019 knowledge and practices concerning medical abortion in Nigeria. Stud Fam Plann. 2011;42(1):41\u201350.","journal-title":"Stud Fam Plann"},{"issue":"4","key":"1530_CR27","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1080\/13625187.2020.1760239","volume":"25","author":"ZM Ibrahim","year":"2020","unstructured":"Ibrahim ZM, Mohamed ML, Taha OT, Ghoneim HM, Mohamed HS, Abdellah AM, et al. Knowledge, attitude and practice towards abortion and post abortion care among Egyptian private obstetricians and gynaecologists. Eur J Contracept Reprod Health Care. 2020;25(4):245\u201350.","journal-title":"Eur J Contracept Reprod Health Care"},{"issue":"2","key":"1530_CR28","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.ijgo.2011.09.015","volume":"116","author":"E Kestler","year":"2012","unstructured":"Kestler E. Obstetrician-gynecologists\u2019 knowledge of and attitudes toward medical abortion in Guatemala. Int J Gynaecol Obstet. 2012;116(2):120\u20133.","journal-title":"Int J Gynaecol Obstet"}],"container-title":["Reproductive Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12978-022-01530-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12978-022-01530-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12978-022-01530-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,24]],"date-time":"2023-01-24T18:02:48Z","timestamp":1674583368000},"score":1,"resource":{"primary":{"URL":"https:\/\/reproductive-health-journal.biomedcentral.com\/articles\/10.1186\/s12978-022-01530-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,24]]},"references-count":28,"journal-issue":{"issue":"S1","published-online":{"date-parts":[[2023,1]]}},"alternative-id":["1530"],"URL":"https:\/\/doi.org\/10.1186\/s12978-022-01530-7","relation":{},"ISSN":["1742-4755"],"issn-type":[{"value":"1742-4755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,24]]},"assertion":[{"value":"18 November 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 January 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethics approval was generally not applicable as these country assessments were led by the ministries of health as programme assessments and not conducted as research activities. In countries where required, ethics approval was obtained. The information collected during the desk review is publicly available data and the key informants all participated within their official capacity and were selected by the ministries of health. Verbal informed consent to participate in the assessment was obtained from all participants.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable as this paper describes a methodological approach to assess availability of MA medicines in countries by using an analytical and conceptual framework.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"20"}}